This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Drug Therapy, Other  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Looking for the Reasons

Gjin Ndrepepa, MD; Albert Schömig, MD; Adnan Kastrati, MD

JAMA. 2007;297:1711-1713.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cardiogenic shock complicating acute myocardial infarction (AMI) is one of the most serious and challenging conditions in cardiovascular medicine, with up to two thirds of patients dying within a few weeks.^1-2 According to data from a national registry of nearly 300 000 patients with ST-segment elevation AMI, the overall incidence of cardiogenic shock (diagnosed at both presentation and after admission) was 8.6%.³

Even though the incidence of cardiogenic shock has remained stable over the time,^2-4 mortality rates among patients with cardiogenic shock have decreased over the last decade. Some of the major factors contributing to this decline are early revascularization with percutaneous coronary intervention or coronary artery bypass graft surgery^{1, 5} and interventions that increase cardiac output, including inotropic agents and supportive mechanical devices such as intra-aortic balloon counterpulsation and left ventricular assist devices.⁶ Babaev et al³ reported that percutaneous coronary intervention rates . . . [Full Text of this Article]

Author Affiliations: Deutsches Herzzentrum, Technische Universität, Munich, Germany.

RELATED ARTICLE

Effect of Tilarginine Acetate in Patients With Acute Myocardial Infarction and Cardiogenic Shock: The TRIUMPH Randomized Controlled Trial
The TRIUMPH Investigators
JAMA. 2007;297(15):1657-1666.
ABSTRACT | FULL TEXT